Global Medical REIT Inc.
GMRE-PADrugs in Pipeline
12
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Docetaxel
Non-small Cell Lung Cancer (NSCLC)
33525
Tinea Pedis
Enzalutamide
Metastatic Hormone Sensitive Prostate Cancer
Fezolinetant
Hot Flashes
Setidegrasib
Pancreatic Cancer
Cisplatin
Urothelial Cancer
Enfortumab Vedotin
Muscle-invasive Bladder Cancer
ASP546C
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
ASP0113
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
gilteritinib
Acute Myeloid Leukemia (AML)
GBT440
Sickle Cell Disease
peficitinib
Arthritis, Rheumatoid
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Docetaxel | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
33525 | Phase 3 | Tinea Pedis | - | - |
Enzalutamide | Phase 3 | Metastatic Hormone Sensitive Prostate Cancer | - | - |
Fezolinetant | Phase 3 | Hot Flashes | - | - |
Setidegrasib | Phase 3 | Pancreatic Cancer | - | - |
Cisplatin | Phase 3 | Urothelial Cancer | - | - |
Enfortumab Vedotin | Phase 3 | Muscle-invasive Bladder Cancer | - | - |
ASP546C | Phase 2 | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | - | - |
ASP0113 | Phase 2 | Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients | - | - |
gilteritinib | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
GBT440 | Phase 2 | Sickle Cell Disease | - | - |
peficitinib | Phase 2 | Arthritis, Rheumatoid | - | - |